RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs

Biological and Pharmaceutical Bulletin

Volumn 33, Issue 6, 2010, Pages 1067-1069

  Nakagami, Yasuhiro ^a   Kawase, Yumi ^a   Yonekubo, Kazuki ^a   Nosaka, Emi ^a   Etori, Maki ^a   Takahashi, Sakiko ^a   Takagi, Nana ^a   Fukuda, Takeshi ^a   Kuribayashi, Takeshi ^a   Nara, Futoshi ^a   Yamashita, Makoto ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Airway inflammation; CC chemokine receptor 4; RS 1748

Indexed keywords

2 [4 [2 (DIETHYLAMINO)ETHOXY]PHENYL] N (2,4 DIFLUOROBENZYL) 5 FLUOROPYRIMIDIN 4 AMINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR4; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); OVALBUMIN; RS 1748; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; GUINEA PIG; IC 50; MALE; NONHUMAN; RESPIRATORY TRACT INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; CHEMOKINE CCL17; CHO CELLS; CRICETINAE; CRICETULUS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUINEA PIGS; HUMANS; INFLAMMATION; INHIBITORY CONCENTRATION 50; MALE; OVALBUMIN; PYRIMIDINES; RECEPTORS, CCR4;

EID: 77953365040     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.33.1067     Document Type: Article

References (15)

1. Luster A. D., Curr. Opin. Allergy Clin. Immunol., 1, 561-567 (2001).
2. Schwarz M. K, Wells T. N., Nat. Rev. Drug Discov.,1,347-358(2002).
3. Bonecchi R., Bianchi G., Bordignon P. P., D'ambrosio D., Land R., Borsatti A., Sozzani S., Allavena P., Gray P. A., Mantovani A., Sini-gaglia F., J. Exp. Med., 187, 129-134 (1998).
4. Imai T., Nagira M., Takaga S., Kakizaki M., Nishimura M., Wang J., Gray P. W., Matsushima K., Yoshie O., Int. Immunol., 11, 81-88 (1999).
5. Lloyd C. M., Rankin S. M., Curr. Opin. Pharmacol.,3,443-448(2003).
6. Pease J. E., Horuk R., Expert Opin. Ther. Pat., 19, 39-58 (2009).
7. Nakagami Y., Kawashima K., Yonekubo K., Etori M., Jojima T., Miyazaki S., Sawamara R., Hirahara K., Nara F., Yamashita M., Eur. J. Pharmacol., 624, 38-44 (2009).
8. Nakagami Y., Kawashima K., Etori M., Yonekubo K., Suzuki C., Jo-jima T., Kuribayashi T., Nara F., Yamashita M., Basic Clin. Pharmacol. Toxicol. (in press).
9. Yokoyama T., Kato N., Yamada N., Neurosci. Lett., 344, 45-48 (2003).
10. Mukaiyama O., Morimoto K., Nosaka E., Takahashi S., Yamashita M., Eur. J. Pharmacol., 498, 287-294 (2004).
11. Furukubo S., Miyazaki H., Nakajima T., Ikeda Y., Morokuma K., Nakamaki C., Heterocyclic Compound, WO2008146914.
12. Panina-Bordignon P., Papi A., Mariani M., Di Lucia P., Casoni G., Bel-lettato C., Buonsanti C., Miotto D., Mapp C., Villa A., Arrigoni G., Fabbri L. M., Sinigaglia F., J. Clin. Invest., 107, 1357-1364 (2001).
13. Chvatchko Y., Hoogewerf A. J., Meyer A., Alouani S., Juillard P., Buser R., Conquer F., Proudfoot A. E., Wells T. N., Power C. A., J. Exp. Med., 191, 1755-1764 (2000).
14. Schuh J. M., Power C. A., Proudfoot A. E., Kunkel S. L., Lukacs N. W., Hogaboam C. M., FASEB J., 16, 1313-1315 (2002).
15. Iellem A., Mariani M., Lang R., Recalde H., Panina-Bordignon P., Sinigaglia F., D'Ambrosio D., J. Exp. Med., 194, 847-853 (2001).